About: Development of a high-throughput homogeneous AlphaLISA drug screening assay for the detection of SARS-CoV-2 Nucleocapsid

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Development of a high-throughput homogeneous AlphaLISA drug screening assay for the detection of SARS-CoV-2 Nucleocapsid Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Development of a high-throughput homogeneous AlphaLISA drug screening assay for the detection of SARS-CoV-2 Nucleocapsid
Creator	Martinez-Sobrido, Luis Zheng, Wei Moran, Thomas Carlos De La Torre, Juan Chen, Catherine Authors, Corresponding Gorshkov, Kirill Gov, -Kirill
source	BioRxiv; Medline
abstract	The coronavirus disease 2019 (COVID-19) pandemic caused by Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) is in urgent need of therapeutic options. High-throughput screening (HTS) offers the research field an opportunity to rapidly identify such compounds. In this work, we have developed a homogeneous cell-based HTS system using AlphaLISA detection technology for the SARS-CoV-2 nucleocapsid protein (NP). Our assay measures both recombinant NP and endogenous NP from viral lysates and tissue culture supernatants (TCS) in a sandwich-based format using two monoclonal antibodies against the NP analyte. Viral NP was detected and quantified in both tissue culture supernatants and cell lysates, with large differences observed between 24 hours and 48 hours of infection. We simulated the viral infection by spiking in recombinant NP into 384-well plates with live Vero-E6 cells and were able to detect the NP with high sensitivity and a large dynamic range. Anti-viral agents that inhibit either viral cell entry or replication will decrease the AlphaLISA NP signal. Thus, this assay can be used for high-throughput screening of small molecules and biologics in the fight against the COVID-19 pandemic.
has issue date	2020-08-20(xsd:dateTime)
bibo:doi	10.1101/2020.08.20.258129
bibo:pmid	32839774
has license	biorxiv
sha1sum (hex)	b2290feade74bfc163317b85deb1b96271118f65
schema:url	https://doi.org/10.1101/2020.08.20.258129
resource representing a document's title	Development of a high-throughput homogeneous AlphaLISA drug screening assay for the detection of SARS-CoV-2 Nucleocapsid
has PubMed identifier	32839774
schema:publication	bioRxiv
resource representing a document's body	covid:b2290feade74bfc163317b85deb1b96271118f65#body_text
is schema:about of	named entity 'protein' named entity 'dynamic range' named entity 'observed' named entity 'large' named entity 'spiking' named entity 'WORK' named entity 'ASSAY' named entity 'BIOLOGICS' named entity 'ENTRY' named entity 'OBSERVED' named entity 'PANDEMIC' named entity 'ANTI-VIRAL AGENTS' named entity 'NEED' named entity 'INFECTION' named entity 'LIVE' named entity 'LARGE' named entity 'COVID-19' named entity 'HTS' named entity 'pandemic' named entity 'system' named entity 'opportunity' named entity 'HTS' named entity 'pandemic' named entity 'viral' named entity 'nucleocapsid' named entity 'lysates' named entity 'Viral' named entity 'COVID-19 pandemic' named entity 'Severe Acute Respiratory Syndrome coronavirus 2' named entity 'SARS-CoV-2' named entity 'cell-based' named entity 'high-throughput screening' named entity 'infection' named entity 'recombinant' named entity 'endogenous' named entity 'assay' named entity 'pg/mL' named entity 'inside the cell' named entity 'lysis' named entity 'PBS' named entity 'lysis buffer' named entity 'lysis' named entity 'host cells' named entity 'viral titer' named entity 'high affinity' named entity 'ACE2' named entity 'Penicillin' named entity 'supernatants' named entity 'virus' named entity 'streptavidin' named entity 'PerkinElmer' named entity 'HTS' named entity 'HTS' named entity 'host-cell' named entity 'microplates' named entity 'clinical phase' named entity 'His-tag' named entity 'viral entry' named entity 'potency' named entity 'coding regions' named entity 'lysate' named entity 'viral proteins' named entity 'antibody' named entity 'SARS-CoV-2' named entity 'antibody' named entity 'convalescent plasma' named entity 'SARS-CoV-2' named entity 'virus' named entity 'approved drugs' named entity 'singlet oxygen' named entity 'HTS' named entity 'virus infection' named entity 'viral particles' named entity 'Trypsin' named entity 'PBS'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software